Shares of medical device company DexCom (NASDAQ:DXCM) fell 7.4% in the morning session after a short-seller report from Hunterbrook Capital alleged issues with the company's G7 glucose monitoring ...

At the 61st annual European Association for the Study of Diabetes Conference (EASD) this week in Vienna, Austria, glucose monitoring company Dexcom introduced its new offering, the Dexcom Smart Basal, ...

Hunterbrook Media released a short report on diabetes-focused DexCom Inc. (NASDAQ:DXCM), citing that the company sold the "adulterated" device. Benzinga reached out to DexCom for comments and is yet ...

Investing.com -- DexCom (NASDAQ:DXCM) stock fell 3% Thursday after Hunterbrook Media published a scathing short report alleging serious safety issues with the company’s G7 continuous glucose ...

Investing.com - UBS maintained its Buy rating and $106.00 price target on DexCom (NASDAQ:DXCM) following a Friday sell-off triggered by concerns about the company’s G7 continuous glucose monitoring ...

Deep-pocketed investors have adopted a bearish approach towards DexCom (NASDAQ:DXCM), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled ...

Shares of DexCom (NASDAQ:DXCM) fell for the third straight session on Friday to reach the lowest level since April, even as the continuous glucose monitoring (CGM) equipment maker managed to retain ...

We recently compiled a list of the 12 Best Healthcare Stocks to Buy and Hold for 5 Years. DexCom, Inc. is one of them. DexCom, Inc. (NASDAQ:DXCM), a leader in continuous glucose monitoring (CGM) ...

DexCom's devices are important to its customers' health. The company still has significant whitespace in its market. Despite potential obstacles, the stock is still attractive. Even so, the ...

Shares of DexCom Inc. DXCM slid 1.80% to $66.08 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.34% to 6,711.20 and ...

Fintel reports that on September 29, 2025, Canaccord Genuity maintained coverage of DexCom (NasdaqGS:DXCM) with a Buy recommendation. Analyst Price Forecast Suggests 57.07% Upside As of September 13, ...

With significant upside potential, DexCom, Inc. (NASDAQ:DXCM) secures a spot on our list of the 13 Best Quality Stocks to Buy According to Hedge Funds. On September 25, 2025, given that previous ...